FDA’s Mobile Health Guidance Removes Risk For Investors
This article was originally published in Start Up
Executive Summary
Investors and their limited partners really don’t like risk, especially not the kind due to uncertainty. Now, for developers of mobile health applications and their investors, at least one risk has been taken off the table: regulatory uncertainty. On September 23, the FDA published the much-anticipated final guidance on mobile medical apps.
You may also be interested in...
Wearable Fitness Technology Could Foretell The Future Of Remote Patient Monitoring
Wearable wireless monitoring devices geared toward the fitness market are beginning to attract the attention of the health care industry, which recognizes the technology’s potential to provide an ideal patient monitoring tool. As more of this technology makes its way into the clinical setting, this trend is poised to change the traditional view of what is and is not a medical device.
Medtech 2013: Device Companies Go Where The Growth Is
To stave off the sluggish growth in established markets, multinational medtechs not only are finding new business in countries with booming health care industries but they’re also forging new ways to serve customers. Device companies now are pushing into services, such as disease management, and angling to compete more aggressively on pricing.
Pfizer Trial Could Take Akili Game Platform Into Digital Health Mainstream
Akili Interactive plans rigorous clinical trials for its mobile gaming app “Project EVO,” amassing empirical observations in the context of the mainstream medical enterprise, where developers believe it will be effective as both a clinical tool and a therapeutic.